SOPHARMA AD: Current report 91 Lavena AD above 5%

opublikowano: 2013-07-04 12:28

Spis treści:

2. INFORMATION ABOUT THE ENTITY

3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Spis załączników:
Current_report_91_Lavena_AD_above_5%.doc (REPORT)

	POLISH FINANCIAL SUPERVISION AUTHORITY
				UNI - EN REPORT No		91	/	2013
	Date of issue:		2013-07-04
	Short name of the issuer
	SOPHARMA AD
	Subject
	Current report 91 Lavena AD above 5%
	Official market - legal basis
	Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
	Unofficial market - legal basis
	Contents of the report:
	Sopharma AD (the “Company") announces that on 18 June 2013 the Company bought 4 039 from the capital increase of Lavena AD. After this transaction, the share of Sopharma AD in the capital of Lavena AD increased to 5.18%.
	Annexes
	File				Description
	Current report 91 Lavena AD above 5%.docCurrent report 91 Lavena AD above 5%.doc				Current report 91 Lavena AD above 5%

SOPHARMA AD

(fullname of the issuer)

SOPHARMA AD

Farmaceutyczny (far)

(short name of the issuer)

(sector according to clasification
of the WSE in Warsow)

1220

Sofia

(post code)

(city)

IlienskoShosse

16

(street)

(number)

+359 2 813 42 00

+359 2 936 02 86

(phone number)

(fax)

(e-mail)

(web site)

nd

(NIP)

(REGON)

	SIGNATURE OF PERSONS REPRESENTING THE COMPANY
	Date	Name	Position / Function	Signature
	2013-07-04	Ognian Donev	Executive Director